Archives
-
Regorafenib (BAY 73-4506) Assay Guide
2026-09-22
A scenario-based guide to using Regorafenib (BAY 73-4506), SKU A8236, in viability, proliferation, migration, and signaling studies. It connects practical assay design with quantitative kinase, melanoma, formulation, and storage data to support more interpretable cancer biology research.
-
BOP Reagent for Peptide and Prodrug Workflows
2026-09-22
BOP reagent offers a practical route to carboxyl group activation, amide bond formation, and phenyl ester preparation in peptide and prodrug research. This guide connects reaction setup and troubleshooting with assay decisions inspired by a carrier-free, ROS-responsive oral cancer prodrug study.
-
Anisomycin Workflows for JNK and Apoptosis
2026-09-21
Anisomycin provides a practical JNK agonist workflow for connecting early stress-signaling events with later apoptosis phenotypes. This guide combines cancer-cell assay design with a carefully bounded interpretation of the reference study on Neuroligin 1 proteolysis and social-memory maintenance.
-
Galectin-1, FIP200, and Autophagy in NAFLD
2026-09-21
A 2026 study identifies a direct Galectin-1–FIP200 interaction as an upstream brake on hepatic autophagy, linking this mechanism to steatosis, dyslipidemia, and insulin resistance. Its combination of mouse gain-of-function models, proteomic profiling, binding analysis, and interaction-disrupting mutations provides a mechanistic framework for metabolic liver disease research.
-
NFIA Coordinates Bone Remodeling and Bone Mass
2026-09-20
The reference study identifies NFIA as a previously underappreciated regulator of bone homeostasis that acts in mesenchymal and osteoprogenitor compartments to coordinate osteoclast, osteoblast, and adipocyte differentiation. Its findings show that NFIA suppresses both bone resorption and formation, but loss of its antiresorptive activity has the stronger net effect, producing impaired bone mass accrual.
-
Chloroquine Diphosphate: Reading Autophagy in HBV Models
2026-09-19
Chloroquine Diphosphate is more informative when used to distinguish autophagosome accumulation from completed autophagic flux. This article connects A8628 assay design with a 2025 HBV study showing how HBsAg redirects TBK1 signaling between interferon production and autophagy.
-
Recombinant Human FGF-19: Practical Workflow
2026-09-18
This dossier-based guide explains how to reconstitute, qualify, and apply Recombinant Human FGF-19 in FGFR4 binding, cell proliferation, and metabolic regulation research. It is intended for controlled in vitro workflows and should not be treated as evidence for efficacy in animals, patients, or disease-specific models without independent validation.
-
Gly-Gly-Phe-Gly: Designing Better Assays
2026-09-18
Gly-Gly-Phe-Gly (GGFG) is examined as a modular peptide linker and an experimental variable, not merely a passive spacer. This article connects GGFG peptide design with mechanism-focused assay logic inspired by panobinostat research in MLL-rearranged leukemia.
-
ATP Solution for mRNA and Kinase Workflows
2026-09-17
Build more reproducible kinase, transcription, ligation, and phosphorylation assays with a ready-to-use 100 mM ATP stock. This workflow-focused guide connects ATP control to the upstream preparation and validation of mRNA-LNP studies, including localized p21 replacement research.
-
Pollen Interference in EEM Hazardous-Substance Detection
2026-09-17
Zhang et al. show that pollen fluorescence can confound hazardous-bioaerosol classification, but targeted spectral preprocessing and fast Fourier transform (FFT) features can substantially improve random-forest recognition. The study reached 89.24% accuracy across 31 sample types and clearly separated several bacterial and toxin targets, supporting more robust fluorescence-based screening.
-
KU-55933: Selective ATM Kinase Inhibitor Workflows
2026-09-16
KU-55933 enables controlled interrogation of ATM signaling across DNA damage response, Akt phosphorylation, cell-cycle, and metabolic assays. This workflow-focused guide explains how to formulate the compound, establish concentration and time windows, and connect mitochondrial stress findings with testable ATM-dependent phenotypes.
-
Aging, Mitochondrial ROS, and Macrophage Phagocytosis
2026-09-16
The reference study identifies a mechanistic chain linking aging-related mitochondrial reactive oxygen species to excess collagen production, impaired F-actin turnover, and defective macrophage phagocytosis. Its combination of human and mouse models, RNA-seq, molecular perturbation, and in vivo validation provides a framework for studying immune aging beyond inflammatory cytokine measurements.
-
Cisapride in iPSC-CM Cardiotoxicity Screens
2026-09-15
Cisapride, also known as R 51619, can serve as a mechanistically informative challenge compound in iPSC-derived cardiomyocyte assays. This article explains how to combine its 5-HT4 activity and hERG channel inhibition with deep-learning phenotyping for more defensible cardiac safety decisions.
-
Mecamylamine Hydrochloride in Gut-Brain Assays
2026-09-15
Mecamylamine hydrochloride provides a brain-penetrant, non-competitive nAChR challenge for separating cholinergic receptor effects from microbiota-driven signaling. This workflow connects receptor pharmacology with vagal, seizure, and neuropsychiatric disorder research while emphasizing vehicle control, concentration-response design, and pathway-level validation.
-
In Vitro Embryonic Dormancy Through mTOR Inhibition
2026-09-14
The Nature Protocols paper establishes a noninvasive, scalable framework for placing mouse blastocysts, human blastoids, and pluripotent stem cells into a reversible diapause-like state through pharmacological mTOR inhibition. Its main practical contribution is a unified workflow for inducing, maintaining, and reversing dormancy while distinguishing genuine developmental quiescence from nonspecific loss of viability.